Lake Street lowered the firm's price target on InspireMD to $4 from $5 and keeps a Buy rating on the shares. InspireMD's voluntary recall of the CGuard Prime 135 cm delivery system is "a disappointing setback to the U.S. launch," but the issue was identified proactively and, "most importantly," is contained to the delivery system, the analyst tells investors. The fixes required for the Prime delivery system are "both manageable and necessary to position the stent for the standard-of-care adoption it deserves," the analyst added. With the product recall InspireMD withdrew its 2026 revenue guidance of $13M-$15M, adds the analyst, who reduced the firm's 2026 revenue estimate from $13M to $8.8M.
